BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination - ScienceDirect

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases

Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children

Frontiers BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages

Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England

Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia

Third vaccine dose reduces transmission and severe COVID-19 nationwide in Israel

Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England

Full article: A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study - The Lancet Respiratory Medicine